Back to top
more

Omnicell (OMCL)

(Delayed Data from NSDQ)

$50.14 USD

50.14
466,690

-2.32 (-4.42%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 250)

Industry: Medical Info Systems

Zacks News

Ford Motor and IRobot have been highlighted as Zacks Bull and Bear of the Day

Ford Motor and IRobot have been highlighted as Zacks Bull and Bear of the Day

Urmimala Biswas headshot

Omicron Hits Elective MedTechs, 3 Subsectors Likely to Thrive

Here we discuss three major subsectors of MedTech and three constituent stocks, OPCH, GMED and OMCL for which the change in the scenario has opened up enormous growth prospects.

Omnicell (OMCL) to Expand EnlivenHealth Division With New Buyout

Omnicell's (OMCL) $82-million buyout of MarkeTouch Media is likely to expand its Advanced Services portfolio.

Here's Why You Should Add Omnicell (OMCL) Stock for Now

Investors are optimistic about Omnicell (OMCL) on strength in medication management and adherence automation solutions.

Is Dynavax Technologies (DVAX) Stock Outpacing Its Medical Peers This Year?

Here is how Dynavax Technologies (DVAX) and Omnicell (OMCL) have performed compared to their sector so far this year.

Omnicell (OMCL) Closes ReCept Holdings Acquisition Deal

Omnicell's (OMCL) completed buyout of the renowned specialty pharmacy management services provider is likely to bolster its Advanced Services offering.

Should iShares S&P SmallCap 600 Growth ETF (IJT) Be on Your Investing Radar?

Style Box ETF report for IJT

3 Reasons Why Growth Investors Shouldn't Overlook Omnicell (OMCL)

Omnicell (OMCL) could produce exceptional returns because of its solid growth attributes.

CERN vs. OMCL: Which Stock Should Value Investors Buy Now?

CERN vs. OMCL: Which Stock Is the Better Value Option?

Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?

Style Box ETF report for SLYG

Should Vanguard S&P SmallCap 600 Growth ETF (VIOG) Be on Your Investing Radar?

Style Box ETF report for VIOG

Is GlaxoSmithKline (GSK) Outperforming Other Medical Stocks This Year?

Here is how GlaxoSmithKline (GSK) and Omnicell (OMCL) have performed compared to their sector so far this year.

Should SPDR Portfolio S&P 600 Small Cap ETF (SPSM) Be on Your Investing Radar?

Style Box ETF report for SPSM

Omnicell (OMCL) is an Incredible Growth Stock: 3 Reasons Why

Omnicell (OMCL) could produce exceptional returns because of its solid growth attributes.

NEOGEN (NEOG) Inks Deal to Boost Global Genomics Business

NEOGEN's (NEOG) latest acquisition of Genetic Veterinary Sciences, Inc. will bolster the global genomics business.

NextGen's (NXGN) Integrated Platform Gets Adopted by Monmouth

NextGen's (NXGN) comprehensive solution suite was adopted by Monmouth to better cater to patients' medical and dental needs.

CERN vs. OMCL: Which Stock Is the Better Value Option?

CERN vs. OMCL: Which Stock Is the Better Value Option?

Omnicell (OMCL) Down 1% Since Last Earnings Report: Can It Rebound?

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NEOGEN (NEOG) Strengthens Global Foothold With Delf Buyout

NEOGEN (NEOG) management believes that Delf's 40 years of experience in the UK dairy hygiene market will help it strengthen its foothold in this region's dairy chemicals market.

Walgreens Boots (WBA) Faces Margin Pressure, Solvency Issue

Of late, increased reimbursement pressure and generic drug cost inflation have been hampering Walgreens Boots' (WBA) margin significantly.

Medtronic (MDT) Gets Health Canada License for GI Genius Module

Medtronic Canada ULC, a subsidiary of Medtronic (MDT), receives Health Canada license for the GI Genius module that aids in colorectal cancer screening.

Here's Why You Should Invest In Bruker (BRKR) Stock for Now

Investors are optimistic about Bruker's (BRKR) better-than-expected results and strong segmental performance.

QIAGEN (QGEN), DiaSorin to Broaden Access to Latent TB Testing

QIAGEN (QGEN) and DiaSorin gained FDA approval for their jointly-created LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin's automated LIAISON XS platform.

Here's Why You Should Hold on to Globus Medical (GMED) for Now

Investors are optimistic about Globus Medical's (GMED) better-than-expected earnings and robust ExcelsiusGPS performance.